Antiviral combination treatment of SARS-CoV-2 after repeated treatment failures of remdesivir monotherapy: A case report

• DOI: 10.1016/j.idcr.2024.e02118
• Publication Date: 2024-11-13T09:11:55Z
• Authors: Anne Cathrine Bay; Michael R. Clausen; Birgit Thorup Røge; Thomas V. Sydenham; Kat Steinke; Rune Micha Pedersen; Line L. Bang; Thomas E. Andersen; Anders Jensen; Lone W. Madsen
• Keywords: 2019-20 coronavirus outbreak; Betacoronavirus

Immunocompromised patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can have a longer duration of viral shedding and persistence symptoms. The optimal treatment strategy for these remains to be established. This case describes male in his late sixties follicular lymphoma persistent symptoms infection SARS-CoV-2 variant BA.2 who was treated remdesivir five times over period six months. clinical effect decreased time, further sequencing revealed the emergence mutations across genome. Due lack other options, patient combination molnupiravir 10 days, epcoritamab discontinued, which led cessation illustrates risk diminished prolonged use need guidelines immunocompromised COVID-19.